The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis

Completed · Phase 2 · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

The purpose of this randomized, placebo-controlled (Phase II) study will be to further evaluate the effects of oral glutathione on growth in children with CF.

Key facts

Study ID

NCT03020719

Run by

University of Minnesota

People needed

60

Starts

2017-06-14

Expected to finish

2018-12-12

Last updated by the study team

2020-01-09

Who can join

Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥ 2 and < 11 years of age at Visit 1
• Documentation of a CF diagnosis as evidenced by the following criteria: Sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) AND Two well-characterized mutations in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
• Weight-for-age between the 10th and 50th percentiles at Screening (Visit 1) (using the Center for Disease Control (CDC) reference equations)
• Current chronic use, greater than 8 weeks before Day 0, of pancreatic enzyme replacement therapy (PERT) for management of pancreatic insufficiency
• Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability to comply with the requirements of the study
• Clinically stable with no significant changes in health status within 2 weeks prior to Day 0

You may not qualify if…

• 1. Intestinal obstruction or gastrointestinal surgery within the 6 months prior to Day 0 2. History of diabetes, Crohn's disease, celiac disease, or bowel resection 3. Use of either oral or inhaled GSH or N-acetyl cysteine within the 4 months prior to Screening (Visit 1) 4. Known hypersensitivity to oral glutathione or lactose 5. Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline, azithromycin, Pulmozyme, Cayston TOBI Kalydeco,Orkambi, Proton Pump Inhibitor, Histamine H-2 Blocker [PPI/H2-blocker], Miralax® , PERT, dietary supplementation, probiotics) within the 4 weeks prior to Day 0 6. Changes in the amount of proprietary dietary supplement formulas (e.g., Scandishakes, Boost, Pediasure, or homemade formula) given (oral or gastrostomy tube) within the 4 weeks prior to Day 0 7. Use of antibiotics (oral, IV, or inhaled) for acute symptoms within the 2 weeks prior to Day 0 8. Use of oral steroids within the 4 weeks prior to Day 0 9. Active treatment for nontuberculous mycobacteria (NTM) at Day 0 10. Active treatment for allergic bronchopulmonary aspergillosis (ABPA) at Day 0 11. Administration of any investigational drug within the 30 days prior to Day 0 12. Sibling who received study drug as part of this study 13. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data

Where it is running

• Childrens Hospital Colorado — Aurora, Colorado, United States
• Connecticut Childrens Medical Center — Hartford, Connecticut, United States
• Nemours Childrens Clinic — Jacksonville, Florida, United States
• Nemours Children's Clinic — Pensacola, Florida, United States
• Emory University Hospital — Atlanta, Georgia, United States
• Riley Children's Hospital — Indianapolis, Indiana, United States
• Childrens Hospital of Michigan — Detroit, Michigan, United States
• Helen DeVos Women and Childrens Center — Grand Rapids, Michigan, United States
• University of Minnesota Medical Center — Minneapolis, Minnesota, United States
• The Childrens Mercy Hospital — Kansas City, Missouri, United States
• Women and Childrens Hospital of Buffalo — Buffalo, New York, United States
• Childrens Hospital of New York/Columbia University Medical Center — New York, New York, United States
• Oregon Health & Science University — Portland, Oregon, United States
• UT Southwestern Medical Center — Dallas, Texas, United States
• Baylor College of Medicine — Houston, Texas, United States
• The University of Vermont Inc. — Burlington, Vermont, United States
• University of Virginia Health System — Charlottesville, Virginia, United States
• Childrens Hospital of Milwaukee — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.